Condition: Borderline Personality Disorder · Sponsor: Central Institute of Mental Health, Mannheim
Individuals with Borderline Personality Disorder (BPD) experience intensive, instable negative emotions. Hyperactivity of the amygdala is assumed to drive exaggerated emotional responses in BPD. Neurofeedback is an endogenous neuromodulation method to address the imbalance of neural circuits. Downregulation of amygdala hyperactivation with neurofeedback may ameliorate dysregulated emotions in BPD. The BrainSTEADy trial is designed to determine whether amygdala-fMRI-BOLD neurofeedback has a specific effect on affect instability in BPD beyond nonspecific benefit.
This description comes directly from the study's public registry record.
Christian Paret-Voigt, Dr. · +4962117034462 · christian.paret@zi-mannheim.de
Miroslava Hofmanová · +4962117034463 · miroslava.hofmanova@zi-mannheim.de
Always discuss trial participation with your own doctor first.
| University clinic Freiburg | Freiburg im Breisgau, Germany | Recruiting |
| University clinic Giessen | Giessen, Germany | Recruiting |
| University Clinic Halle (Saale) | Halle, Germany | Not Yet Recruiting |
| University Medical Center Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
| Central Institute of Mental Health | Mannheim, Germany | Recruiting |
| University Clinic Tuebingen | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06626789